VEGFA and diabetic macular edema: This increase is the result of the introduction of humanized monoclonal antibodies against vascular endothelial growth factor (VEGF), which has become first-line therapy in the treatment of neovascular age-related macular degeneration, diabetic macular edema, and other vascular pathologies of the eye.